Somewhat Favorable Media Coverage Extremely Likely to Affect Vitro Diagnostics (VODG) Share Price

Headlines about Vitro Diagnostics (OTCMKTS:VODG) have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vitro Diagnostics earned a news impact score of 0.67 on their scale. InfoTrie also gave media headlines about the company an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the immediate future.

VODG traded down $0.03 during trading on Thursday, hitting $0.24. The stock had a trading volume of 21,702 shares, compared to its average volume of 3,226. Vitro Diagnostics has a 12 month low of $0.03 and a 12 month high of $0.45.

ILLEGAL ACTIVITY NOTICE: This report was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at

Vitro Diagnostics Company Profile

Vitro Diagnostics, Inc, doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases.

Further Reading: What are different types of coverage ratios?

Receive News & Ratings for Vitro Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitro Diagnostics and related companies with's FREE daily email newsletter.

Leave a Reply